Patents Assigned to VORONOIBIO INC.
  • Patent number: 12281121
    Abstract: The present invention relates to an N-containing heteroaryl derivative and a pharmaceutical composition comprising same as an active ingredient for the prevention or treatment of cancer. The derivative exhibits high inhibitory activity against various protein kinases, particularly excellent ret proto-oncogene (RET) enzyme inhibitory ability, and has an excellent effect of inhibiting the proliferation of medullary thyroid cancer cells and lung cancer cells, which express RET fusion genes, and thus the derivative can be effectively used in the treatment of cancer, for example, medullary thyroid cancer or lung cancer, and particularly, can be effectively used in the treatment of cancer in which RET fusion genes are expressed.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: April 22, 2025
    Assignees: VORONOI Inc., VORONOIBIO Inc.
    Inventors: Seo Hyun Jo, Hua Li, Hee Sun Ryu, Hwan Kim, Ji Yoon Seok, Sun Hwa Lee, Jung Beom Son, Nam Doo Kim
  • Publication number: 20220073505
    Abstract: The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell limes, and thus can be usefully used in the treatment of lung cancer.
    Type: Application
    Filed: November 8, 2021
    Publication date: March 10, 2022
    Applicants: VORONOI INC., B2SBIO INC., VORONOIBIO INC., B2SBIO INC.
    Inventors: Youn Ho LEE, Ju Hee KANG, Se In KANG, Yi Kyung KO, Eun Hwa KO, Hwan Geun CHOI, Jung Beom SON, Nam Doo KIM